Thrombosis
News
Study supports extended apixaban use
ATLANTA—Due to results of the AMPLIFY-EXTENSION study, researchers are recommending a new indication for apixaban: long-term use to prevent...
News
Factor appears safe, effective in hemophilia B
The goal of the phase 3 study, called B-LONG, was to evaluate the safety and efficacy of a long-lasting recombinant factor IX Fc fusion protein (...
News
Secondary prophylaxis reduces bleeding in hemophilia
PARIS—Results of a phase 3 study indicate that the recombinant antihemophilic factor octocog alfa is effective as secondary bleeding prophylaxis...
News
Hemophilia patients plagued by professional challenges
their disorder has had a negative impact on their career. In fact, 1 in 5 patients said they have lost a job because of their condition....
News
Drug for aHUS effective but expensive
AMSTERDAM—Eculizumab elicits “phenomenal” results in atypical hemolytic uremic syndrome (aHUS), according to two presentations given at the 17th...
News
A new approach to heparin production
News
Eculizumab gets accelerated approval for aHUS
News
Research indicates apixaban is superior to warfarin
These results were presented at the European Society of Cardiology Congress in Paris on August 28 and published simultaneously online in The New...
News
Rivaroxaban noninferior to warfarin in AF patients
News
New antiplatelet agent approved by FDA
News
Rivaroxaban approved for thromboembolic events
Clinical studies evaluated the use of rivaroxaban in more than 6,000 patients.